Second, only 2 studies of blood sample were included in the present study, additional studies with larger sample sizes are essential to evaluate whether DAPK promoter methylation can become a noninvasive biomarker for GC diagnosis in the future. The gene discussed is DAPK1; the disease is gastric cancer.